Articles related to PRODUCT RECALL

Healthcare providers should be vigilant for patients presenting with neurological symptoms, especially if there’s a history of consuming canned tuna products.

N-nitroso-duloxetine poses increased cancer risk at higher concentrations and extended exposure periods, prompting FDA-mandated strict limits on nitrosamine levels in medications.

Recent research indicates that pharmaceutical nitrosamine contamination presents broader implications for drug safety, with increasing evidence of genotoxic and mutagenic effects even at trace levels.

Manufacturing violations at an Indian facility have triggered a recall of 15 million OTC pain patches, raising concerns about product quality and patient safety across multiple widely-used brands.

The expansion of this recall highlights the critical importance of verifying medication packaging against blister strip labeling, particularly for controlled substances where precise dosing is essential.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”